Search

Author/Creator Llovet, J.M.

1. First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. (December 2016)

Authors:
Kim, R.; Sharma, S.; Meyer, T.; Sarker, D.; Macarulla, T.; Sung, M.; Choo, S.P.; Shi, H.; Schmidt-Kittler, O.; Clifford, C.; Wolf, B.; Llovet, J.M.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. PMEPA1 has an oncogenic role in hepatocellular carcinoma in the context of TGFβ signaling: data from single cell RNAseq and transgenic models. (October 2022)

Authors:
Pinyol, R.; Andreu-Oller, C.; Piqué-Gili, M.; Esteban-Fabró, R.; Bárcena-Varela, M.; Montironi, C.; Ruiz de Galarreta, M.; Peix, J.; Abril-Fornaguera, J.; Huguet-Pradell, J.; Lindblad, K.E.; Torres-Martin, M.; Sia, D.; Lujambio, A.; Llovet, J.M.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S120
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search